DelveInsight’s, “EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline landscape. It covers the EGFR + NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in EGFR + NSCLC research @ https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight

Key Takeaways from the EGFR + NSCLC Pipeline Report

• On June 26, 2026- Taiho Oncology, Inc. announced a phase 3 study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.
• On June 22, 2026- National Cancer Centre, Singapore initiated a phase 2 study is to determine best overall response rate (BOR) based on radiological assessment per RECIST v1.1 to combination of S-1 and Osimertinib in treatment-resistant EGFR mutant lung cancer.
• On June 17, 2026- Merck Sharp & Dohme LLC conducted a phase 3 study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as EGFR mutations or EGFR-mutated) or any of the follow genomic alterations: ALK gene rearrangements, ROS1 rearrangements, BRAF V600E mutations, NTRK gene fusions, MET exon 14 skipping mutations, RET rearrangements, or less common EGFR point mutations of exon 20 S768I, exon 21 L861Q, or exon 18 G719X mutations. The primary hypothesis is that sacituzumab tirumotecan is superior to chemotherapy with respect to overall survival (OS) in NSCLC with EGFR mutations.
• On June 11, 2026- Bayer initiated a study treatment, sevabertinib (BAY2927088), is expected to block the mutated EGFR and HER2 proteins which may stop the spread of NSCLC.
• On June 11, 2026- Beijing Biotech conducted a Phase 1/2 study evaluating the safety, feasibility, and preliminary anti-tumor activity of off-the-shelf dual-target CAR-NK cells in participants with advanced or metastatic NSCLC whose tumors co-express at least two of the following antigens: Mesothelin (MSLN), EGFR, and HER2/ERBB2.
• On June 08, 2026- ArriVent BioPharma Inc. announced a phase 3 study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator’s choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC mutations, and who have not received any prior therapy for advanced disease. Participants will be randomized in a 1:1 ratio to treatment with firmonertinib or osimertinib or afatinib and will take the assigned dose daily.
• DelveInsight’s EGFR + NSCLC pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for EGFR + NSCLC treatment.
• The leading EGFR + NSCLC Companies such as Summit Therapeutics, Apollomics Inc., BeBetter Med Inc., Lantern Pharma Inc., Betta Pharmaceuticals Co., Ltd., Avistone Biotechnology Co., Ltd., BlossomHill Therapeutics, J Ints Bio, Nuvectis Pharma, Inc., Pierre Fabre Medicament, and Shanghai Best-Link Bioscience, LLC and others.
• Promising EGFR+NSCLC Pipeline Therapies such as IN10018, Furmonertinib, Oral S-1 + Oral Osimertinib, YH25448, JS111 capsules (AP-L1898), Osimertinib, Gefitinib, RC108, Sunvozertinib, and others.

Stay informed about the cutting-edge advancements in EGFR + NSCLC treatments @ EGFR + NSCLC Clinical Trials Assessment

EGFR Non-Small Cell Lung Cancer (NSCLC) Overview

EGFR-positive non-small cell lung cancer (EGFR+ NSCLC) is a subtype of lung cancer characterized by mutations in the epidermal growth factor receptor (EGFR) gene. This receptor plays a critical role in cell growth and division. Mutations in EGFR lead to uncontrolled cell proliferation, contributing to cancer development. EGFR mutations are present in approximately 10-15% of NSCLC cases in Western populations and around 30-50% in Asian populations. This subtype of lung cancer is most commonly found in non-smokers, women, and patients with adenocarcinoma, a form of NSCLC.

EGFR + NSCLC Emerging Drugs Profile

• AK112: Summit Therapeutics

AK112, also known as ivonescimab is a novel, potential first-in-class bispecific antibody being developed by Summit Therapeutics for EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC). The drug’s mechanism of action combines dual blockade of programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF) within a single molecule, thereby simultaneously enhancing anti-tumor immune responses and inhibiting tumor angiogenesis. In EGFR-positive NSCLC, AK112/ivonescimab is specifically being evaluated in patients with locally advanced or metastatic EGFR-mutated non-squamous NSCLC who progressed after third-generation EGFR tyrosine kinase inhibitor therapy. The drug received U.S. FDA Fast Track designation for this indication in combination with platinum-based chemotherapy for adult patients with EGFR-mutated locally advanced or metastatic NSCLC following EGFR-TKI progression. The FDA has accepted for filing a biologics license application (BLA) for ivonescimab (AK112) in combination with chemotherapy for the treatment of patients with EGFR-mutated, locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC).1 The application specifically targets patients whose disease has progressed following treatment with a third-generation tyrosine kinase inhibitor (TKI), such as osimertinib (Tagrisso). The FDA has assigned a Prescription Drug User Fee Act goal action date of November 14, 2026.

• APL-101: Apollomics Inc.

APL-101 oral capsules, are a novel, potent, selective, orally bioavailable small-molecule c-Met tyrosine kinase inhibitor being developed for non-small cell lung cancer (NSCLC) and other solid tumors with MET dysregulation. In EGFR-positive NSCLC, the mechanism of action of APL-101 involves selective inhibition of the c-Met receptor kinase pathway, which is frequently activated as a resistance mechanism following EGFR tyrosine kinase inhibitor therapy, by blocking aberrant c-Met signaling, the drug aims to suppress tumor cell proliferation, invasion, metastasis, and treatment resistance. Apollomics is also evaluating APL-101 in combination with osimertinib for EGFR-mutated NSCLC. For this indication and broader NSCLC with MET genomic tumor aberrations, the drug received U.S. FDA Orphan Drug Designation. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC).

• ANS02: Avistone Biotechnology Co., Ltd.

ANS02 is a novel fourth-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) being developed by Avistone Biotechnology Co., Ltd. for EGFR-positive non-small cell lung cancer (EGFR+ NSCLC) and other solid tumors. The drug is designed to selectively inhibit mutant EGFR signaling, including resistant EGFR mutations that emerge after earlier-generation EGFR-TKI therapy, thereby suppressing tumor cell proliferation and survival in EGFR-driven cancers. The indication focus includes EGFR-mutated NSCLC, particularly treatment-resistant disease. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC).

• NXP900: Nuvectis Pharma, Inc.

NXP900 is an investigational oral small-molecule for EGFR-positive non-small cell lung cancer (EGFR+ NSCLC) and other solid tumors with SRC/YES1 pathway activation. The drug’s mechanism of action involves selective inhibition of SRC family kinases (SFKs), including SRC and YES1, through a unique Type 1.5 inhibition mechanism that blocks both the catalytic and scaffolding functions of SRC kinase, thereby producing comprehensive shutdown of downstream oncogenic signaling pathways involved in tumor proliferation, metastasis, and resistance to EGFR inhibitors. In EGFR-mutated NSCLC, NXP900 is specifically being evaluated in combination with osimertinib to overcome acquired resistance following prior EGFR-TKI therapy. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC).

The EGFR + NSCLC Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of EGFR + NSCLC with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for EGFR + NSCLC Treatment.
• EGFR + NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• EGFR + NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the EGFR + NSCLC market.

Learn more about EGFR + NSCLC Drugs opportunities in our groundbreaking EGFR + NSCLC Research @ EGFR + NSCLC Unmet Needs

EGFR + NSCLC Companies

Summit Therapeutics, Apollomics Inc., BeBetter Med Inc., Lantern Pharma Inc., Betta Pharmaceuticals Co., Ltd., Avistone Biotechnology Co., Ltd., BlossomHill Therapeutics, J Ints Bio, Nuvectis Pharma, Inc., Pierre Fabre Medicament, and Shanghai Best-Link Bioscience, LLC and others.

EGFR Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

EGFR + NSCLC Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Stay informed about how we’re transforming the future of oncology @ EGFR + NSCLC Market Drivers and Barriers, and Future Perspectives

Scope of the EGFR + NSCLC Pipeline Report

• Coverage- Global
• EGFR + NSCLC Companies- Summit Therapeutics, Apollomics Inc., BeBetter Med Inc., Lantern Pharma Inc., Betta Pharmaceuticals Co., Ltd., Avistone Biotechnology Co., Ltd., BlossomHill Therapeutics, J Ints Bio, Nuvectis Pharma, Inc., Pierre Fabre Medicament, and Shanghai Best-Link Bioscience, LLC and others.
• EGFR+NSCLC Pipeline Therapies- IN10018, Furmonertinib, Oral S-1 + Oral Osimertinib, YH25448, JS111 capsules (AP-L1898), Osimertinib, Gefitinib, RC108, Sunvozertinib, and others.
• EGFR + NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• EGFR + NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of EGFR + NSCLC Pipeline on our website, @ EGFR + NSCLC Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. EGFR Non-Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. EGFR Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. AK112: Summit Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. APL-101: Apollomics Inc.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. NXP900: Nuvectis Pharma, Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies
21. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Products
22. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Unmet Needs
23. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Market Drivers and Barriers
24. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Future Perspectives and Conclusion
25. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Analyst Views
26. EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight